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Abstract
This chapter presents a review on the design of nanoparticles which have been 
proposed as drug delivery systems in biomedicine. It will begin with a brief histori-
cal review of nanotechnology including the most common types of nanoparticles 
(metal nanoparticles, liposomes, nanocrystals and polymeric nanoparticles) and 
their advantages as drug delivery systems. These advantages include the mechanism 
of increased penetration and retention, the transport of insoluble drugs and the 
controlled release. Next, the nanoparticle design principles and the routes of admin-
istration of nanoparticles (parental, oral, pulmonary and transdermal) are discussed. 
Different routes of elimination of nanoparticles (renal and hepatic) are also analyzed.
Keywords: nanoparticle, drug delivery, insoluble drug, controlled release, route of 
administration
1. Introduction
Nanomedicine is a relatively new discipline that arises from the intersection 
between nanotechnology and medicine. It is based on the control of matter at the 
nanometer scale for applications in the field of human health. The use of materi-
als in this range has been a great advance for the pharmacology by modifying 
fundamental properties of the drugs such as solubility, diffusivity, half-life in 
the bloodstream and drug release and distribution profiles [1–4]. Although the 
production and use of nano-sized matter dates from hundreds of years [5, 6], 
nanomedicine as a modern interdisciplinary science was first established at the end 
of the last century. Many authors consider the beginning of nanotechnology in the 
famous lecture of the physicist and Nobel laureate Richard P. Feynman in 1959 for 
the American Physical Society entitled: “There’s Plenty of Room at the Bottom: An 
Invitation to Enter a New Field of Physics” [7]. In it, Feynman presented a futuristic 
vision of technology that leads towards the atomic scale and towards the final limits 
established by physical laws. Revolutionary ideas were put forward, such as reduc-
ing the integrated circuits of a computer to diameters between 10 and 100 atoms. To 
understand the scope of his predictions, suffice it to remember that, at the time of 
presenting these ideas, a computer occupied an entire room if not several. However, 
the word (or the prefix) nano was not mentioned even once in his presentation, 
Feynman stuck to describing the miniaturization of machines and its possible appli-
cations. The honor of having coined the term “nano” is awarded to Norio Taniguchi, 
for his presentation “On the basic concept of nanotechnology” in 1974 [8].
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Drug Company Application Date of approval
Lipid-based
Doxil Janssen Kaposi’s sarcoma, ovarian cancer, 
multiple myeloma
1995
DaunoXome Galen Kaposi’s sarcoma 1996
AmBisome Gilead Sciences Fungal/protozoal infections 1997
Visudyne Bausch and Lomb Wet age- related macular 
degeneration, myopia, ocular 
histoplasmosis
2000
Marqibo Acrotech Biopharma Acute lymphoblastic leukemia 2012
Onivyde Ipsen Metastatic pancreatic cancer 2015









Acute lymphoblastic leukemia 1994
Copaxone Teva Multiple sclerosis 1996
PegIntron Merck Hepatitis C infection 2001
Eligard Tolmar Prostate cancer 2002
Neulasta Amgen Neutropenia, chemotherapy 
induced
2002
Abraxane Celgene Lung cancer, metastatic breast 
cancer, metastatic pancreatic 
cancer
2005
Cimiza UCB Crohn’s disease, rheumatoid 
arthritis, psoriatic arthritis, 
ankylosing spondylitis
2008
Plegridy Biogen Multiple sclerosis 2014
ADYNOVATE Takeda Hemophilia 2015
Inorganic
INFeD Allergan Iron-deficient anemia 1992
DexFerrum American Regent Iron-deficient anemia 1996
Ferrlecit Sanofi Iron deficiency in chronic kidney 
disease
1999
Venofer American Regent Iron deficiency in chronic kidney 
disease
2000
Feraheme AMAG Iron deficiency in chronic kidney 
disease
2009
Injectafer American Regent Iron-deficient anemia 2013
Table 1. 
FDA-approved nanomedicines for drug delivery. Adapted from reference [16] with permission of Springer 
Nature.
It is important to emphasize that the term nanotechnology applied to the study 
of nanoparticles simply consists in renaming the study of colloidal dispersions, in 
which field the contributions of renowned scientists such as Michael Faraday stand 
out, who in 1857 disseminated the first synthesis of gold nanoparticles and other 
metals [9]. In the paper, Faraday reveals his amazement at the changes in the optical 
properties of metallic colloidal dispersions. These properties were later explained in 
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1908 by Gustav Mie who would give a solution to Maxwell’s equations for particles 
with a finite volume [10]. In 1925, Richard Zsigmondy would be awarded the Nobel 
Prize in Chemistry for his demonstration of the heterogeneous nature of colloidal 
dispersions [11]. His contributions in methodological terms have become funda-
mental for the study of modern colloidal chemistry and nanotechnology.
In 1981, Eric Drexler [12] proposed what is now known as a bottom-up approach, 
where atoms are self-assembled to create higher-order structures. It contrasts with 
the approach proposed by Feynman, who conceives the beginning of nanotech-
nology from a top-down approach, building smaller and smaller machines that, 
ultimately, are used to manipulate matter with atomic precision. In particular, the 
bottom-up approach is of great interest in nanoparticle synthesis, where self-assem-
bly properties, the product of natural chemical and physical interactions between 
molecules, can be exploited to produce defined characteristics. It is this concept that 
opens a wide range of possibilities towards the synthesis of nanoparticles with a wide 
variety of functionalities. From this point of view, nanoparticle engineering is based 
on “programming” with predetermined instructions the self-assembly of atoms or 
molecules in such a way that the desired nanoparticles are the final product.
Different authors see the paths of nanotechnology and medicine intertwined in 
1986 when Matsumura and Maeda [13] observed that an anticancer protein bound 
to polymeric nanoparticles exhibited greater accumulation in tumor tissues than 
in healthy tissues. This discovery led to the theory of enhanced permeability and 
retention (EPR) as a consequence of tumor physiology and the size of nanoparticles 
(<200 nm), which are capable of penetrating tumor cells due to their reduced size 
and, at the same time, being retained [13]. The discovery lays the foundation for 
the development of different theories on targeted delivery via passive transport to 
tumor tissues and a large cascade of advances in the design of drug nanocarriers. 
In 1995, the first liposome-based nanostructure for the delivery of doxorubi-
cin, an important anticancer drug, was approved by the FDA (Food and Drug 
Administration, USA) under the trade name Doxil® [14]. Since then and until April 
2016, more than 50 nanomedicines of different kinds have been approved by the 
FDA and this is expected to be only the beginning of the near future [15]. Table 1, 
which has been adapted from reference [16], summarizes the FDA-approved nano-
medicines used for drug delivery up to date. At the time of writing this chapter, 
one of the most conservative market capitalization estimates that the value of all 
nanomedicines is comprised of $ 47.5 billion and is expected to rise to $ 164 billion 
by 2027 driven by the crisis SARS-CoV-2 [17].
2. Types of nanoparticles
Modern and advanced synthesis techniques have led to the preparation of a 
great variety of nanoparticles with different shapes and sizes, together with the use 
of a great variety of materials. The classification of nanoparticles can be based on 
different physical and/or chemical parameters. This is a brief summary of the most 
important characteristics and functions of different types of nanoparticles used in 
biomedicine, classified based on the materials used in their synthesis.
2.1 Metal nanoparticles
Metallic nanoparticles have attracted great interest for use in medicine as 
anticancer agents [18], imaging contrast agents [19], and drug carriers [20]. One of 
the most exploited properties of these nanoparticles is the increase in molar absorp-
tivity that colloidal dispersions present due to the intensity of their surface plasmon 
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resonance [21], classic examples of this being nanoparticles of metals such as gold, 
silver or copper. Plasmon resonance can radiate light (Mie scattering), a process that 
finds great utility in the optical and imaging fields, or it can be rapidly converted to 
heat (absorption). The latter mechanism can be used to convert metallic nanopar-
ticles into light-activated heat sources for use in medicine in selective laser photo-
thermolysis of cancer cells [22–24]. The properties of the resonance plasmon can 
be tuned by modifying the size, morphology and nature of the metals used for the 
synthesis of nanoparticles, thus being able to serve different purposes [18]. Their 
optical properties and high capacity to catalyze reactions and electron transfer also 
give them applications as biosensors [21] which, through ingenious modifications, 
are capable of significantly amplifying signals [25].
Metallic nanoparticles are also of interest as vehicles for the administration of 
drugs and other active principles due to their high surface-volume ratio, stability, 
functionality through chemical modifications of their surface and relative harm-
lessness. For example, Libutti et al. [26] functionalized the surface of 27 nm gold 
nanoparticles with tumor necrosis factor-α and polyethylene glycol. The nanopar-
ticles managed to passively accumulate in the cancerous tissues avoiding healthy 
tissues. This allowed the researchers to administer doses of tumor necrosis factor-α 
that were previously considered toxic. Iron oxide nanoparticles have been approved 
by the United States Food and Drug Administration (FDA) for the treatment 
of anemia [27]. Recently, molecular docking studies propose the reuse of these 
nanoparticles to combat the current global pandemic of SARS-CoV-2 [28]. The 
studies revealed that both Fe2O3 and Fe3O4 nanoparticles interact effectively with 
the different proteins and glycoproteins of the virus. These interactions associated 
with conformational changes in proteins are expected to result in the inactivation of 
the virus.
However, despite the great boom in metallic nanoparticles due to their long 
history and simplicity in terms of their synthesis, they present toxicity problems in 
prolonged use as they cannot be biodegraded [29–31]. In addition, different authors 
have already expressed their concerns regarding the neurotoxicity of these particles 
as they are capable of crossing the blood–brain barrier [32, 33].
2.2 Liposomes
Liposomes are spherical vesicles composed of one or more concentric mem-
branes of lipid bilayers with an internal compartment that normally contains 
water. Liposomes have the ability to encapsulate both lipophilic molecules in their 
membrane and hydrophilic in their internal cavity. The size of these vesicles can 
vary from a few nanometers to several microns. However, liposomes applied for 
medical use range between 50 and 450 nm [34]. Liposomes were discovered in 
the 1960s [35] and claim to be the first nanoparticles to be used for the delivery of 
nanomedicines after Doxil® was approved by the FDA in 1995 [14]. At present, 
there have been technological advances that have managed to use various natural or 
synthetic lipids, as well as surfactants to modify the physicochemical properties of 
liposomes, giving rise to the second and third generation of them [36]. Changes in 
the physicochemical properties of liposomes influence their interaction with cells, 
their half-life in circulation, their ability to penetrate tissues, and their final fate in 
vivo [36]. For example, through the exchange of a phospholipid bilayer in liquid 
phase for a bilayer in solid phase in liposomes, by incorporating cholesterol (bilayer 
tightening effect) or sphingomyelin, the retention of the drug loaded in the lipo-
somes increases, delaying the release.
Despite all the hopes for conventional liposomes, they have presented various 
problems and pharmacological implications over the years. A major drawback of 
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conventional liposomes is their rapid capture by the reticuloendothelial system 
[37]. Liposomes accumulate mainly in the liver and spleen, due to their abundant 
blood supply and the abundance of phagocytic cells resident in these tissues 
[38]. The marked increase in the retention and accumulation of liposomal drugs 
in these organs may delay the clearance of lipophilic anticancer drugs from the 
circulation [39]. Furthermore, during chemotherapy, it can lead to partial deple-
tion of macrophages and interfere with important host defense functions in these 
cell types [40].
2.3 Nanocrystals
Nanocrystals are perhaps the simplest forms of nanomedicine, i.e., nanoparticles 
made up of 100% of the drug. The large surface/area ratio offered by the nanomet-
ric scale increases the dissolution rate, allowing improved pharmacokinetic profiles. 
The small size of the nanoparticles increases the penetration of the nanocrystals 
to biological barriers such as the digestive tract, thus increasing the bioavailability 
of insoluble drugs. The production of crystalline nanoparticles has been applied to 
both organic drugs and inorganic materials [41–43]. Although the inorganic crystal-
line nanoparticles approved by the FDA (year 2016) are limited to hydroxyapatite 
and calcium phosphate for use as substitutes for bone grafts and iron oxide, iron 
oxide nanoparticles have been used for the treatment of glioblastoma and anemia, 
due to iron deficiency in kidney diseases [15]. Solubility problems associated with 
several pharmacological compounds have been improved by conversion to nano-
crystals and are marketed for a variety of indications [43]. The pearl mill developed 
by Elan Nanosystems was used to produce the first three FDA-approved nanocrys-
tals: Rapamune®, Tricor® and Emend®, and is expected to be almost universally 
applicable to a variety of drugs with low solubility, estimated to be 70–90% of 
potential drug compounds [41].
2.4 Polymeric nanoparticles
Polymeric nanoparticles are colloidal particles of solid nature that, depend-
ing on the preparation method, can form two types of structures: nanospheres 
or nanocapsules [44]. Nanospheres consist of a matrix system in which the drug 
can be adsorbed on the surface or co-precipitated with the polymer [45], while in 
nanocapsules the drug is contained in an internal cavity surrounded by a polymeric 
membrane [46]. Natural polymers like carbohydrates and proteins vary in their 
properties between hydrophilic, hydrophobic and even amphiphilic. On the other 
hand, synthetic polymers are mostly hydrophilic in nature and can be present in a 
prepolymerized form or be polymerized during the nanoparticle synthesis process. 
Synthetic polymers, in turn, can be subdivided into two classes, biodegradable and 
non-biodegradable. Polylactic-co-glycolic acid (PLGA) is a biodegradable polymer 
widely used for drug delivery [47, 48]. On the other hand, polyacrylates are non-
biodegradable polymers that have also been studied for drug delivery [49, 50], 
although to a lesser extent compared to biodegradable polymers for clear biocom-
patibility reasons [51].
Polymeric nanoparticles have immense potential as drug carriers, since they 
can deliver them in different organs, they protect drugs against degradation in 
vitro and in vivo, they release the drug in a controlled manner and also offer the 
possibility of passively targeting drugs to tumors or other tissues actively [44]. 
The use of polymeric nanoparticles for drug delivery is a universal approach to 
increase the therapeutic performance of those that are poorly soluble in any route 
of administration.
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3. Advantages of nanoparticles for drug delivery
Nanoparticles bring a new level of engineering and control to the field of medi-
cine by being able to modify parameters such as solubility, diffusivity, half-life, 
toxicity, pharmacokinetics and biodistribution of drugs and diagnostic agents. The 
applications of nanoparticles are very diverse and are expected to increase with the 
advancement of technology. In recent years, numerous studies have demonstrated 
their ability to act as sensors [52], drug carriers [53–55], and diagnostic agents [1, 56]. 
Recent efforts have managed to integrate treatments and diagnoses in a single applica-
tion, giving rise to the procedures known as “theranostic”.
The justification for the use of nanoparticles as drug delivery systems lies in 
at least three mechanisms: (i) Enhanced Penetration and Retention (EPR) of 
nanoparticles in solid tumors; (ii) The possibility of transporting insoluble drugs in 
the blood through stable colloidal systems and (iii) the controlled release thereof. In 
this section, the possible advantages of each of these points will be developed.
3.1 Enhanced permeability and retention (EPR)
The term EPR was coined by Matsumura and Maeda in 1986 [13]. In their work, 
the researchers observed that the anticancer protein neocarzinostatin, conjugated 
to a polymeric matrix, exhibited greater accumulation in tumor tissues than free 
neocarzinostatin. By applying labeled macromolecules to tumor-bearing mice, 
they observed that their concentration was up to 5 times higher in tumor areas 
than in blood over a period of 19 to 72 hours [13]. The authors affirm that the 
passive accumulation of these macromolecules in tumors is due to the abnormal 
physiology associated with tumor masses: fenestrated hypervascularization with 
increased permeability to macromolecules (or nanoparticles) and poor recovery 
through blood vessels or lymphatic vessels [57]. Subsequently, it was shown that 
other plasma proteins greater than 40 kDa are capable of passively and selectively 
accumulating in tumor areas [58]. The EPR effect can be demonstrated in mice with 
the intravenous injection of the Evans Blue marker, which binds to plasma albumin 
forming a complex that demonstrates differential accumulation in tumor areas [59], 
as shown in Figure 1.
Figure 1. 
Image of a metastatic lung cancer originating from 26 colon tumors implanted in the dorsal skin of a mouse. 
The mouse was sacrificed 3 months after implantation and 10 hours before sacrificing, a solution of Evans 
blue (5%) was injected intravenously to allow the EPR effect to become visible. Albumin-Evans blue complex 
(70 kDa) preferentially accumulated in metastatic tumor nodules, as in primary tumors. Arrows point to 
metastatic tumor nodules. From reference [60] with permission of Elsevier.
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For passive accumulation through the EPR effect to be important, different 
requirements are needed. On the one hand, the nanoparticles must remain in cir-
culation for a time greater than 6 hours [60, 61]. This can generally be achieved by 
functionalizing the nanoparticles with polyethylene glycol (PEG) [62]. On the other 
hand, the mechanism also depends on the particles being small enough to penetrate 
biological membranes but large enough to be retained. Yuan et al. [63] measured 
the microvascular permeability of several macromolecules in human colon adeno-
carcinoma LSI74T transplanted in mice with immunodeficiency and the results 
indicated that the cut-off size of the pore is around 400-600 nm, depending on 
physicochemical properties such as charge and hydrophobicity of the nanoparticles. 
Regarding the minimum size, Maeda et al. [58] estimated that the nanoparticle size 
must be greater than 40 kDa to show significant retention in the tumor area.
Vascular extravasation is also highly dependent on the morphology and the 
specific type of tumor. Scanning electron micrographs of normal vascular epithe-
lium and two epithelia associated with different tumors are shown in Figure 2. As 
can be seen, tumor-associated epithelia have significant pores (fenestrations) and 
their size depends on the type of tumor. Smith et al. [64] studied the extravasation 
capacity of quantum-dots (20-25 nm) and single-walled carbon nanotubes (2-3 x 
200 nm) in tumors implanted in mouse ears. The surface of both types of nano-
structures was modified by PEG to avoid differences in charge or surface chemistry 
and that the results were only due to the morphology of the particles. The authors 
found that spherical quantum-dots are capable of extravasation of the endothelium 
of LS174T tumors, whereas cylindrical nanotubes are capable of extravasation in 
U87MG tumors. Surprisingly, the authors were not able to see the extravasation of 
the nanomaterials in normal endothelium. This suggests that the morphology of the 
nanoparticles may be a determining factor for penetrating certain tumors, while 
healthy endothelium could prevent nanoparticle transfer.
Although the EPR model has been tested in rodents with large induced tumor 
masses [59, 65], these models differ widely in morphology and physiology of 
possible human tumors and, for these reasons, there is still much controversy 
regarding it [55, 60, 66]. Firstly, tumors of up to 10% of body weight have been 
reported in mice. If we make an analogy with a 70 kg human, the tumor would 
be the size of a basketball [67], when they actually have a size between mil-
limeters and centimeters at the time of diagnosis and treatment [68]. Such tumor 
masses filter out a significant proportion of the injected drug dose and act as a 
reservoir, enhancing efficacy while mitigating toxicity. In addition to this, the 
Figure 2. 
Scanning emission microscopy (SEM) of tumors and normal blood vessels. SEM images show pores in the 
U87MG and LS174T tumor vasculature at the apparent border between endothelial cells. No pores are seen at 
the border of the vasculature of a tumor-free mouse ear. Scale bars: U87MG (500 nm), Normal (1 μm) and 
LS174T (1 μm). Reprinted with permission from reference [64]. Copyright 2012 American Chemical Society.
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tumor microenvironment in humans presents important physiological differences 
compared to murine tumors: (i) lack of fenestrations in the tumor endothelium for 
the entry of nanoparticles, (ii) heterogeneity of blood flow through tissues, which 
causes the regions to become acidic or hypoxic [69], (iii) lower pericyte coverage, 
(iv) heterogeneous basement membrane and (v) higher and heterogeneous density 
of the extracellular matrix. This leads to high interstitial pressure and therefore the 
main mechanism of matter transport is by diffusion and not by convective trans-
port, which is more efficient [69, 70].
For these reasons, it is not possible to directly transfer the results obtained in 
rodents to humans, mainly because cell penetration depends on the nanoparticles 
go from the point of application to the tumor mass and be able to interact with cells 
to be internalized. Currently, different methods are being investigated to increase 
the EPR effect. For example, Fang et al. [71] developed agents which can selectively 
generate vasodilator molecules (carbon monoxide) in tumor areas, achieving an 
increase in the concentration of the nanocarrier between 2 and 3 times higher in 
these, while an increase in tissues healthy was not detected. Similar results have 
been achieved with nanocarriers that can release nitric oxide [72, 73]. The increase 
in blood pressure results in an increase in the osmotic pressure, which promotes the 
filtration of the particles towards the tumor areas so that when angiotensin II is co-
administered with the nanocarriers, an increase in the transfer and accumulation in 
the tumor areas can be observed [74].
In contrast to the passive accumulation of drug nanocarriers in tumor areas by 
the EPR mechanism, active targeting is presented, which is based on the function-
alization of the nanoparticle surface with recognition molecules such as antibodies 
[75, 76] or ligands [77, 78] which can specifically bind to molecules overexpressed 
at the target site [79]. In the active targeting strategy, two cellular targets can be 
distinguished: (i) targeting cancer cells, which present overexpression of molecules 
such as transferrin, folate, epidermal growth factor receptor or glycoprotein 
receptors, and (ii) targeting tumor endothelium, which have overexpression of 
vascular endothelial growth factors (VEGF), αvβ3 integrins, vascular cell adhesion 
molecule-1 (VCAM-1), or matrix metalloproteinases [66, 80]. In some cases, both 
receptors are overexpressed in cancer cells and endothelium and can be exploited 
simultaneously [80]. In addition, the design of nanocarriers as active targeting sys-
tems may involve the coupling of recognition molecules as surface receptors which 
are able to initiate endocytosis, and hence to increase cell internalization in contrast 
to simple accumulation [81]. Not only would this increase the antitumor efficacy of 
many drugs, but it could also be used for the delivery of genetic material [82].
3.2 Insoluble drug transport
Most orally administered drugs that are soluble in water and capable of pen-
etrating biological membranes during the passage of the gastrointestinal tract will 
eventually become bioavailable in the body. In contrast, water-insoluble drugs will 
generally not be bioavailable after oral ingestion as they cannot dissolve and pass 
through the gastrointestinal barrier. Along the same lines, due to their low solubil-
ity, they cannot be administered intravenously and parenteral administration does 
not always increase bioavailability [83]. It is estimated that 90% of drugs in devel-
opment are insoluble in water, while only 40% of drugs on the market share this 
characteristic [84]. These statistics could indicate that many drugs in development 
do not reach their administration to patients due to their low solubility in water. 
This not only means less capital invested in research and development but also 
lost treatment opportunities. The development of a drug in 2011 was estimated at 
between 92 million and 1.8 billion dollars [85], lasting for a period of between 11.4 
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and 13.5 years on average [86]. Considering these, we can see that low water solubil-
ity represents a formidable challenge and opportunity for nanotechnology.
Three factors govern the speed and degree of absorption of orally administered 
drugs: (i) dissolution rate, (ii) solubility and (iii) intestinal permeability, which 
are grouped according to the biopharmaceutical classification system (BCS, 
Biopharmaceutical Classification System) in the categories [87]:
Class I: High Solubility - High Permeability.
Class II: Low Solubility - High Permeability.
Class III: High Solubility - Low Permeability.
Class IV: Low Solubility - Low Permeability.
The criterion established by the BCS classifies a drug as soluble when it is 
capable of dissolving an entire therapeutic dose in 250 mL of water, being this 
volume equivalent to the average amount of water found in the stomach [87].
As can be deduced, the possibilities of entering the market for a class I drug are 
substantially greater than that of the rest of the categories, however, a possible solu-
tion to these problems lies in the development of drug carriers which can transport 
them in a stable colloidal dispersion and with particles capable of crossing biologi-
cal membranes [88]. As an example, Atovaquone (Wellvone®) is an antibiotic used 
for the treatment of Pneumocystis carinii, leishmaniasis and P. falciparum malaria, 
however, its low solubility limits its absorption. By formulating a dispersion of 
nanoparticles of this drug, it was possible to increase absorption from 15 to 40% 
with a 3-fold lower drug dose [89]. Xie et al. [90] prepared curcumin-loaded silk 
fibroin nanoparticles (SFN) to increase the dissolution rate of the drug and the 
mass of the drug in dispersion. Recent results from our research group revealed that 
SFN are an excellent vehicle for the transport of the natural drug naringenin, with 
anti-cancer properties [91], which has low solubility in water. The results indicated 
that this drug loaded in the nanoparticles is 1.7 times more effective in reducing 
the viability of HeLa cells than by itself. These results can be attributed to the low 
solubility and slow dissolution of free naringenin which, when loaded in the SFN, 
remains stable in dispersion, increasing its cellular penetration and improving the 
dissolution profile.
3.3 Controlled release
Nanoparticles can be used as drug reservoirs for their controlled release over 
time, which offers numerous advantages compared to conventional administration 
of multiple doses. Among them, it can be highlighted the improvement in efficacy 
and reduction of toxicity and patient cooperation [92]. The former can be consid-
ered as the increase in therapeutic activity compared to the intensity of the side 
effects, while the latter offers the advantage of reducing the number of applications 
required during treatment.
Controlled release is especially beneficial for those drugs whose half-life in 
the blood is relatively low due to a high rate of metabolism and elimination by 
the body. This effect can be observed in Figure 3, where the concentration of a 
drug in blood applied by a conventional method (red line) is represented against 
a controlled release system (blue line). As can be seen, the drug administered in a 
conventional manner is only a fraction of the time in the zone considered thera-
peutic, while fluctuating between subtherapeutic concentrations and above the 
maximum tolerable level. On the other hand, the controlled release system takes 
longer to reach the therapeutic concentration window but remains stable within 
it. The goal of the system is to match the rate of clearance to that of release in the 
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therapeutic concentration zone. In the clinic, this translates into numerous benefits, 
for example, in the case of administration of analgesics, the concentration could 
be prevented from falling to subtherapeutic levels and therefore the patient feeling 
pain. This is transferable to a large number of drugs including anti-inflammatories, 
antibiotics, anesthesia, hormones, chemotherapeutics, etc.
There are different mechanisms by which polymer nanoparticles can allow 
controlled drug release. On the one hand, the release can be delayed by using 
a water-soluble polymer as a matrix, whose dissolution rate is slow and conse-
quently releases the drug at the rate of dissolution of the polymer. In the case of 
insoluble polymers, they can act as a diffusion barrier, slowing down the release 
of the drug from inside the nanoparticle to the medium. The release can also be 
controlled by an osmotic flow generated by a semipermeable membrane, which 
is itself the nanosystem, as is the case with liposomes. Finally, a delivery system 
that responds to internal or external stimuli could be achieved, which would be 
very useful, for example, in diabetic patients in which the nanosystem would 
release insulin on demand of the blood glucose concentration [93]. Volpatti et 
al. [94] have succeeded in synthesizing nanoparticles whose insulin release is 
sensitive to glucose levels by adding glucose oxidase and catalase to them. These 
researchers demonstrated that a single subcutaneous injection provides 16 h 
of glycemic control in diabetic mice. Cheng et al. [95] developed SFN capable 
of loading the antitumor drug paclitaxel (3%) and delivering it sustainably for 
14 days.
4. Nanoparticle design
From the point of application to the site of action, nanoparticles face a host of 
challenges. In the first place, they are diluted in approximately 5 L of blood that 
circulates at 5 L/min through the circulatory system about 106 km long, where the 
velocity in each blood vessel can be between 1.5-33 cm/s [96] hindering the interac-
tion between nanoparticles and the target tissue. Interstitial fluids have a much 
lower speed, just a few μm/s, where interactions would be favored. However, reach-
ing them means crossing biological barriers, which is not an easy task. Finally, to 
all of the above, it is added that when nanoparticles enter the body they are treated 
hostilely by the immune system. For these reasons, different design principles are 
applied to nanoparticles to try to get around different obstacles depending on their 
final application.
Figure 3. 
Diagram of the blood concentration of a drug after multiple administrations as a conventional injection (red 
line) and as a controlled release system (blue line).
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As mentioned above, as soon as the nanoparticles enter the body, they are 
exposed to the mononuclear phagocyte system which consists of a system of phago-
cytic cells, predominantly macrophages resident in the spleen, lymph nodes and 
liver, which sequester the nanoparticles immediately after administration [97]. This 
process begins with the opsonization of the nanoparticles based on the adsorption 
of plasma proteins, including albumin, complementary system proteins, pattern 
recognition receptors and immunoglobulins. This process is relatively fast and can 
occur in a period as short as 30 seconds [98]. This “natural functionalization” is 
known as the formation of the protein crown and clearly can alter the function or 
fate of nanoparticles by disturbing different parameters such as size, charge and 
surface chemistry, as well as hydrophobicity. This protein crown can even mask the 
receptors or ligands attached to the nanoparticles [99].
Different design strategies have been developed to avoid opsonization and 
subsequent clearance by the immune system. This evasion of the immune system 
tries to increase the circulation time of the nanoparticles in the body and, conse-
quently, the chances that they find the target tissue while they circulate through the 
bloodstream. One of the easiest and most direct strategies is PEGylation, based on 
the functionalization with polyethylene glycol (PEG) molecules on the surface of 
the nanoparticles where the polymer units form very strong associations with the 
water molecules, generating a hydration layer and a steric barrier to opsonization 
[100, 101]. An alternative strategy may be to functionalize the nanoparticles with 
endogenous signals normally present in healthy cells. Rodríguez et al. [102] func-
tionalized viral particles with the CD47 membrane protein, which acts as a “non-
phagocytizing” signal [103], thus prolonging the circulation time. Another similar 
strategy is to cover the particles with biomimetic molecules such as cell membranes, 
to hide the particles from the immune system [104, 105]. Another way to increase 
circulation time is the one proposed by Nikitin et al. [106], which is based on a 
slight and transient suppression of the mononuclear phagocyte system through 
the administration of anti-erythrocyte antibodies. They were able to increase the 
circulating half-life of different nanosystems up to 32 times through the suppression 
of ca. 5% of hematocrits.
Silk fibroin exhibits unique low immune response properties, allowing it to 
evade the immune system. This can be exemplified by the study by Catto et al. 
[107], who implanted tubular matrices based on silk fibroin in mice, detecting 
few macrophages labeled with anti-ED1 antibodies, which was indicative of a low 
inflammatory response. The absence of T lymphocytes (anti-CD4 antibodies) 
demonstrated that there was no cell-mediated immune response. Recently, under 
a state-of-the-art design, Tan and colleagues [108] have designed a doxorubicin 
delivery nanosystem using silk fibroin as a Trojan horse. The researchers synthe-
sized drug-loaded amorphous calcium carbonate nanoparticles and coated them 
with silk fibroin. It prevents the premature release of doxorubicin and helps evade 
the immune system. Thanks to the EPR mechanism, nanoparticles are accumu-
lated in cancerous tissues and, finally, internalized by lysosomes. The acidic pH 
of the latter promotes the generation of CO2 from calcium carbonate, resulting 
in the bursting of the lysosome due to the expansion of the gas and the release 
of doxorubicin inside the target cell. Results in mice revealed that silk fibroin-
coated nanoparticles are more effective in reducing tumor mass and preventing 
side effects in mice compared to free doxorubicin or uncoated calcium carbonate 
nanoparticles. In addition, the immunotoxicity tests indicated that the nanopar-
ticles did not initiate an immune response by not increasing the amount of T 
cells (CD4+ and CD8+) or IgM, IgG and IgA compared to the control group. More 
information on intracellular drug release can be found in the review by Fenghua 
et al. [109].
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5. Routes of administration of nanoparticles
SFN have proven to be extremely versatile for the transport of therapeutic com-
pounds such as small drugs, proteins and DNA molecules [110]. The functionality 
of these compounds is closely related to the route of administration. For example, 
nanoparticles can be injected into the bloodstream and make use of the EPR effect 
for passive accumulation in metastatic tumors or they can be injected directly into 
the tumor mass [111]. On the other hand, they can be applied topically for the treat-
ment of skin cancer [112] and in a similar way for lung treatments [113, 114]. SFN 
have been used in a wide variety of routes of administration [54]. For the sake of 
simplicity, only the main routes of administration will be mentioned: parental, oral, 
transdermal and pulmonary, and some of the studies that address the use of SFN for 
these different routes of administration will be cited as examples.
5.1 Parenteral
Parenteral administration forms are intended for administration by injection, 
which can be subdivided into intravenously (into a vein), intramuscular (into the 
muscle), subcutaneous (under the skin), or intradermal (into the skin). Parenteral 
administration acts faster than topical or enteral administration, and the onset of 
action often occurs in a range of seconds to minutes. Essentially, the bioavailabil-
ity of the injected drug is 100% and its distribution is systemic, which means that 
it is potentially capable of reaching the entire body. This last concept paired with 
the EPR effect as mentioned above is of special interest for the treatment of tumor 
masses. For example, ZhuGe et al. [115] prepared SFN with their surface func-
tionalized by proanthocyanidins and loaded with indocyanine green. Indocyanine 
can absorbe near-infrared light (650-900 nm) and producing a thermal effect 
both in vitro and in vivo. This photothermic compound is approved by the FDA 
and can be used to kill cells by photothermolysis. To test their functionality, the 
researchers injected the loaded nanoparticles intravenously into mice bearing 
C6 glioma. The pharmacokinetic study showed that the nanoparticles managed 
to reach the gliomas after intravenous administration in vivo, while the pharma-
cological study demonstrated inhibition of tumor growth after irradiation with 
near-infrared light. On the other hand, nanoparticles also offer temporary release 
control. Recently, in another study, Zhan et al. [116] administered Celastrol-
loaded SFN to rats intravenously. The results showed that an increase in the total 
exposure time to the drug is reduced by increasing its residence time and reducing 
its metabolism.
5.2 Oral
Oral administration is the most common route and probably the one preferred 
by patients when receiving medications. However, conventional formulations, such 
as tablets and capsules, can release drugs in a rapid and poorly controlled manner, 
which can result in degradation and alteration of the drug due to the environ-
ment of the gastrointestinal tract (variations in pH and the presence of digestive 
enzymes and microbiota). Furthermore, the common mechanism of drug absorp-
tion through the gastrointestinal tract is passive diffusion. Consequently, most 
of the initial dose is not absorbed but is metabolized and excreted. SFN possess 
favorable characteristics to overcome the aforementioned problems and become 
candidates of interest for the oral administration of therapeutic compounds. Firstly, 
due to their mucoadhesive capacity, SFN can adhere firmly to the gastrointestinal 
mucosa or intestinal epithelial cells (Peyer’s lymphatic M cells), followed by cell 
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internalization via endocytosis [117]. Thus, encapsulated drugs can enter the 
bloodstream effectively and intact. Zhan et al. [116] increased more than doubled 
the absolute bioavailability of Celastrol from 3.14% to 7.56% by loading the drug in 
SFN and administering it orally to rodents.
5.3 Pulmonary
The lung is a potential target for drug delivery for both local and systemic 
treatments. Locally, lung and respiratory diseases, e.g., lung cancer or tuberculosis, 
can be treated with a reduced dose and fewer side effects compared to conventional 
dosage forms. At the systemic level, due to the large surface area of  the lung, the 
drug can be absorbed quickly and efficiently without being degraded by the first-
pass metabolism as in oral administration [118]. In 2015, Kim et al. [113] prepared 
cisplatin-loaded SFN for the treatment of lung cancer. The particles showed com-
patibility with the human lung epithelial cell line A549. The results indicated that 
the cisplatin loaded in the particles increases the cytotoxicity concerning the drug 
applied alone. The researchers concluded that the particles showed a high aerosol-
ization performance through in vitro lung deposition measurement, which is at the 
level of commercially available dry powder inhalers.
5.4 Transdermal
The transdermal administration of drugs improves their bioavailability and is 
useful for systemic and local treatment as in pulmonary application. Takeuchi et al. 
[119] evaluated the in vivo permeability of 40 nm SFN through the skin using mice 
and demonstrated that the particles are capable of reaching the dermis in 6 hours in 
addition to the stratum corneum, hair follicles and epidermis that surrounds them.
6. Nanoparticle elimination
The use of nanoparticles in humans raises great doubts about their safety and 
their elimination capacity. If the removal is very fast, the nanoparticles will not reside 
long enough to fulfill their function. On the contrary, if the retention is very high, 
the concentration of nanoparticles can increase to the point of becoming harmful. 
Consequently, a relevant question in the use of nanoparticles in humans is how 
these biological systems can eliminate nanoparticles once their functions have been 
fulfilled. The properties of nanoparticles that affect their removal are mainly based 
on size, shape, composition, charge, and surface chemistry. These aspects will be 
briefly discussed within the two main elimination routes, (i) renal and (ii) hepatic 
elimination, to obtain a global vision of the process.
6.1 Renal elimination
The kidneys have the potential for rapid removal of particles from the vascular 
system without the need for decomposition. Renal elimination involves the mecha-
nisms of glomerular filtration and tubular secretion to end in urinary excretion 
[120]. The nanoparticles reach the nephrons through the afferent arteriole, where 
they meet three endothelial barriers: the fenestrated endothelium; the highly 
negatively charged glomerular basement membrane; and the podocyte extensions 
of glomerular epithelial cells. The fenestrated epithelium has pores with a func-
tional physiological diameter of between 9 and 10 nm, and a few (ca. 1%) pores of 
15 to 23 nm in diameter [121], which means that nanoparticles with diameters less 
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than 10 nm can spread freely regardless of the charge of the particle. The second 
barrier presented by the glomerular basement membrane filters particles between 6 
and 8 nm depending on the electrostatic interactions between the nanoparticle and 
the membrane [122]. In this way, low-charged or positively charged nanoparticles 
can diffuse more freely. After glomerular filtration, the nanoparticles enter the 
lumen of Bowman’s capsule, where they can be reabsorbed. Because the proximal 
tube epithelium is negatively charged, positively charged nanoparticles can be more 
easily reabsorbed.
Choi et al. [123] administered quantum-dots (inorganic nanoparticles) intra-
venously to rodents to study their renal elimination. The results indicated that 
particles with a hydrodynamic diameter less than 5.5 nm present rapid elimination 
and the increase in this diameter is inversely proportional to the retention time of 
the quantum-dots in the body.
6.2 Hepatic clearance and the reticulum endothelial system
Those nanoparticles that are too large to be excreted by the renal system must be 
eliminated by the hepatobiliary system. In 1924, Karl Albert Ludwig Aschoff coined 
the term reticuloendothelial system (RES) to describe a functional cellular system 
widely distributed in the body, composed of sessile and circulating macrophages 
of mesenchymal origin. These cells have a marked phagocytic capacity towards 
particulate matter. Macrophages stored in the RES can be found in the central 
nervous system (microglia), in the spleen, lymph nodes, tonsils, in the bone mar-
row (reticular cells) and, particularly, in the liver (90% of all macrophages) [124]. 
The exogenous structures are subjected to very intensive phagocytosis by the RES as 
well as the foreign proteins of higher molecular weight. Total blood flow must pass 
through the liver, making it a central organ to monitor the blood for endogenous, 
foreign substances and particles that must be removed for physiological reasons. 
In order to perform their functions, RES cells have special abilities such as: phago-
cytosis, pinocytosis, the release of signaling substances (cytokines, eicosanoids) 
and elimination of endotoxins, among others [124]. In addition, these are equipped 
with numerous pores of various diameters, depending on their different functions, 
which gives them the ability to filter larger molecules and particles, keeping them 
away from the liver parenchyma. The Kupffer cells and the endothelial sinus are 
in a privileged position to engulf any colloid foreign to the body. For this purpose, 
Kupffer cells are equipped with a branched and ciliated surface that act as capture 
mechanics. Besides, they possess specific receptors for carbohydrate components, as 
well as for the Fc region of IgG and for complement C3, allowing them to differenti-
ate the opsonized matter. They also possess lysosomal enzymes, although in much 
lower amounts than sinus endothelial cells.
In a very complete study, Poon et al. [125] proposed an algorithm to infer how 
nanoparticles can be eliminated in vivo (Figure 4). Most of the nanoparticles with 
diameters smaller than the glomerular filtration size limit (∼5.5 nm) are eliminated 
by the kidneys and leave the body through the urine [123] although fecal elimina-
tion of small nanoparticles is also observed [125]. Biodegradable nanocarriers or 
nanoparticles larger than 5.5 nm can be decomposed [126, 127] or metabolized [128] 
and can be returned to the systemic circulation. Most non-biodegradable nanoparti-
cles larger than 5.5 nm are retained long-term in Kupffer cells [129]. If the nanopar-
ticles can evade Kupffer cells or if Kupffer cells are incapacitated, the nanoparticles 
can undergo hepatobiliary clearance. Similar to the glomerular filtration size limit, 
the authors proposed that there is a filtration size limit in hepatic sinusoidal endo-
thelium. Nanoparticles larger than the fenestra of sinusoidal endothelium in the 
liver have restricted access to hepatocytes, whereas nanoparticles smaller than the 
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fenestrae have better access through the fenestra to enter the perisinusoidal space. 
In general, nanoparticles must escape these barriers established by non-parenchy-
mal cells in the liver before they have the potential to enter the perisinusoidal space 
and interact with hepatocytes for elimination. Once the nanoparticles successfully 
interact with them, they can transit to enter the bile ducts. Finally, the nanoparticles 
enter the intestine and are eliminated from the body through the feces.
7. Conclusions
The academy and industry have made extraordinary advances in a wide variety 
of areas due to the development of nanotechnology and the control of structures at 
the nanoscopic levels. Particularly in the field of medicine, nanotechnology has the 
potential to generate a significant impact on human health, being able to improve the 
diagnosis, prevention and treatment of diseases. In this field, nanotechnology seeks 
to encapsulate drugs and/or tracer compounds in nanoparticles to increase their 
efficiency by allowing direct delivery to target tissues, while they reduce their toxic-
ity avoiding accumulation and the consequent side effects in healthy tissues. The 
encapsulation of drugs also allows their controlled release, thus avoiding maximum 
levels of highly harmful or subtherapeutic concentrations. Moreover, nanoparticles 
are of great value in the transport of drugs with low solubility in water, which turns 
out to be the major problem when introducing new drugs to the market because it 
limits their bioavailability in the body. A wide variety of materials can be used for the 
preparation of nanoparticles depending on the intended function of the system.
Figure 4. 
Flow diagram for removal of nanoparticles in vivo. Reprinted with permission from reference [125]. Copyright 
2019 American Chemical Society.
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